Persistence of ctDNA in breast cancer patients during neoadjuvant treatment is a significant predictor of poor tumour response.

Qing Zhou Simon Peter GampenriederSophie FrantalGabriel RinnerthalerChristian F SingerDaniel EgleGeorg PfeilerRupert BartschViktor WetteAngelika PichlerEdgar PetruPeter C DubskyZsuzsanna Bago-HorvathChristian FeslMargaretha RudasAnders StåhlbergRicarda GrafSabrina WeberNadia DandachiMartin Filipits Michael Gnant Marija Balić Ellen Heitzer

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Overall, our results demonstrate that the detection and persistence of ctDNA at MT may have the potential to negatively predict response to neoadjuvant treatment and identify patients who will not achieve pCR or be classified with RCB II/III.

Keyphrases

rectal cancer
lymph node
locally advanced
squamous cell carcinoma
risk assessment
real time pcr
circulating tumor cells
sensitive detection
cell free